58
Views
33
CrossRef citations to date
0
Altmetric
Research Article

A Case of Mao Inhibitor/MDMA Interaction: Agony After Ecstasy

, &
Pages 149-159 | Published online: 25 Sep 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Esther Papaseit, Clara Pérez-Mañá, Marta Torrens, Adriana Farré, Lourdes Poyatos, Olga Hladun, Arantza Sanvisens, Roberto Muga & Magi Farré. (2020) MDMA interactions with pharmaceuticals and drugs of abuse. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 357-369.
Read now
Kodye L. Abbott, Patrick C. Flannery, Kristina S. Gill, Dawn M. Boothe, Muralikrishnan Dhanasekaran, Sridhar Mani & Satyanarayana R. Pondugula. (2020) Adverse pharmacokinetic interactions between illicit substances and clinical drugs. Drug Metabolism Reviews 52:1, pages 44-65.
Read now
Saskia J. Rietjens, Laura Hondebrink, Remco H. S. Westerink & Jan Meulenbelt. (2012) Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions. Critical Reviews in Toxicology 42:10, pages 854-876.
Read now
Edmund Silins, Jan Copeland & Paul Dillon. (2007) Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Australian and New Zealand Journal of Psychiatry 41:8, pages 649-655.
Read now

Articles from other publishers (29)

Gregory S. BarberCharles C. Dike. (2023) Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. Psychiatric Services 74:8, pages 838-846.
Crossref
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm & Christopher S. Stauffer. (2022) Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 239:6, pages 1945-1976.
Crossref
Funda InanTibor M. Brunt, Ramon R. ContrucciLaura HondebrinkEric J. F. Franssen. (2020) Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review. Therapeutic Drug Monitoring 42:2, pages 271-281.
Crossref
Michael J. Moss & Robert G. Hendrickson. (2019) Serotonin Toxicity. Journal of Clinical Psychopharmacology 39:6, pages 628-633.
Crossref
Nicholas J. Connors & Robert S. Hoffman. 2017. Critical Care Toxicology. Critical Care Toxicology 1413 1438 .
Dirk D. Coetzee, Víctor López & Carine Smith. (2016) High-mesembrine Sceletium extract (Trimesemine™) is a monoamine releasing agent, rather than only a selective serotonin reuptake inhibitor. Journal of Ethnopharmacology 177, pages 111-116.
Crossref
Nicholas J. Connors & Robert S. Hoffman. 2016. Critical Care Toxicology. Critical Care Toxicology 1 26 .
Márcia Carvalho, Helena Carmo, Vera Marisa Costa, João Paulo Capela, Helena Pontes, Fernando Remião, Félix Carvalho & Maria de Lourdes Bastos. (2012) Toxicity of amphetamines: an update. Archives of Toxicology 86:8, pages 1167-1231.
Crossref
Donald G. BarcelouxNicholas A. Buckley. 2012. Medical Toxicology of Drug Abuse. Medical Toxicology of Drug Abuse 126 155 .
Shaun L Greene, Fergus Kerr & George Braitberg. (2008) Review article: Amphetamines and related drugs of abuse. Emergency Medicine Australasia 20:5, pages 391-402.
Crossref
Helena Carmo, Marc Brulport, Matthias Hermes, Franz Oesch, Douwe de Boer, Fernando Remião, Félix Carvalho, Michael R. Schön, Niels Krebsfaenger, Johannes Doehmer, Maria de Lourdes Bastos & Jan G. Hengstler. (2007) CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA). Toxicology 229:3, pages 236-244.
Crossref
Roland W. Freudenmann & Manfred Spitzer. (2006) The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA). CNS Drug Reviews 10:2, pages 89-116.
Crossref
Rafael de la Torre, Mag? Farr?Pere N. Roset, Neus Pizarro, Sergio Abanades, Mireia Segura, Jordi Segura & Jordi Cam?. (2004) Human Pharmacology of MDMA. Therapeutic Drug Monitoring 26:2, pages 137-144.
Crossref
Jessica R. Oesterheld, Scott C. Armstrong & Kelly L. Cozza. (2004) Ecstasy: Pharmacodynamic and Pharmacokinetic Interactions. Psychosomatics 45:1, pages 84-87.
Crossref
J.C. Cole & H.R. Sumnall. (2003) Altered states: the clinical effects of Ecstasy. Pharmacology & Therapeutics 98:1, pages 35-58.
Crossref
Elaine Ho, Linda Karimi-Tabesh & Gideon Koren. (2001) Characteristics of pregnant women who use Ecstasy (3, 4-methylenedioxymethamphetamine). Neurotoxicology and Teratology 23:6, pages 561-567.
Crossref
MICHAEL SHANNON. (2000) Methylenedioxymethamphetamine (MDMA, “Ecstasy”). Pediatric Emergency Care 16:5, pages 377-380.
Crossref
Neil Buxton & Norman S McConachie. (2016) Amphetamine abuse and intracranial haemorrhage. Journal of the Royal Society of Medicine 93:9, pages 472-477.
Crossref
Andrew P. Ten Eick, Hidefumi Nakamura & Michael D. Reed. (1998) DRUG–DRUG INTERACTIONS IN PEDIATRIC PSYCHOPHARMACOLOGY. Pediatric Clinics of North America 45:5, pages 1233-1264.
Crossref
Paula D Mueller & William S Korey. (1998) Death by “Ecstasy”: The Serotonin Syndrome?. Annals of Emergency Medicine 32:3, pages 377-380.
Crossref
Josep Arimany, Jordi Medallo, Amadeu Pujol, Albert Vingut, Juan Carlos Borondo & Juan Luis Valverde. (1998) Intentional Overdose and Death With 3,4-Methylenedioxyethamphetamine (MDEA; "Eve"). The American Journal of Forensic Medicine and Pathology 19:2, pages 148-151.
Crossref
Kirk C. Mills. (1997) SEROTONIN SYNDROME. Critical Care Clinics 13:4, pages 763-783.
Crossref
Roger Lane & David Baldwin. (1997) Selective Serotonin Reuptake Inhibitor-Induced Serotonin Syndrome. Journal of Clinical Psychopharmacology 17:3, pages 208-221.
Crossref
NT Mathew, GE Tietjen & C Lucker. (2016) Serotonin Syndrome Complicating Migraine Pharmacotherapy. Cephalalgia 16:5, pages 323-327.
Crossref
A. R. Green, A. J. Cross & G. M. Goodwin. (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”). Psychopharmacology 119:3, pages 247-260.
Crossref
NADIA SOLOWIJ, WAYNE HALL & NICOLE LEE. (2010) Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug. British Journal of Addiction 87:8, pages 1161-1172.
Crossref
Graeme P. Dowling. 1990. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA 63 75 .
Alexander T. Shulgin. 1990. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA 1 20 .
Jerrold B. Leikin, Anne J. Krantz, Michele Zell-Kanter, Robert L. Barkin & Daniel O. Hryhorczuk. (2012) Clinical Features and Management of Intoxication Due to Hallucinogenic Drugs. Medical Toxicology and Adverse Drug Experience 4:5, pages 324-350.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.